Bruno Permanne is currently the head of biology at Asceneuron SA. After getting his PhD in biochemistry at the University of Lille under the co-supervision of Drs. Andre Delacourte and Luc Buée, he conducted postdoctoral research in the laboratory of Professor Blas Frangione at the NYU Medical Center. Both groups are recognized for their work on the pathophysiology of tau protein and the role of amyloid buildup in neurodegenerative diseases. Dr. Permanne has more than 19 years of experience in drug-discovery programs on neurodegenerative diseases (including Alzheimer’s disease, Parkinson’s disease and tauopathies). At Asceneuron, he is leading the development of assays for biomarker programs. At his previous position as project leader at Merck Serono, he successfully ran a drug-discovery program resulting in the progression of small molecules from high-throughput screens to lead optimization stage.